AI

Alumis Inc. Common Stock

ALMS·NASDAQ

$20.08

-1.2%
HealthcareBiotechnology

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$2.48B
EPS-2.8600
P/E Ratio-7.02
Earnings Date08/12/2026

alms

Other Current Liabilities

Last Annual Value

57.08M

3-Year CAGR

152%

5-Year CAGR

74%

10-Year CAGR

32%

AI

Alumis Inc. Common Stock Competitors Analysis of Other Current Liabilities

ALMS · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
57.08M
117.0%N/AN/A 
0.00
N/AN/AN/A
28.79M
41.6%28.8%N/A
9.05M
183.8%14.0%N/A
11.55M
6.4%15.1%N/A
6.78M
-5.0%18.3%N/A
OCGN logo
Ocugen, Inc.
NASDAQ:OCGN
6.69M
86.7%31.3%18.4%
4.84M
15.7%13.8%2.9%
48.79M
N/A67.4%18.9%
AI

Alumis Inc. Common Stock Fair Value Envelope

ALMS · NASDAQ

Our analysis suggests that ALMS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.08, this represents a potential HIDDEN relative to our calculated worth for Alumis Inc. Common Stock.

Intrinsic Value
Current Price: $20.08